Chicago Rivet & Machine (CVR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for May 13, 2025, to elect seven directors, approve executive compensation, determine frequency of say-on-pay votes, and ratify Crowe LLP as auditor.
Shareholders of record as of March 17, 2025, are entitled to vote; 966,132 shares outstanding, each with one vote.
Proxy materials and annual report are available online; proxies solicited by mail and other means, with costs borne by the company.
Voting matters and shareholder proposals
Proposals include election of seven directors, advisory vote on executive compensation, advisory vote on frequency of say-on-pay, and ratification of Crowe LLP as auditor.
Board recommends voting for all director nominees, for executive compensation, for a three-year say-on-pay frequency, and for auditor ratification.
Shareholder proposals for 2026 must be received by December 5, 2025; nominations and other proposals have specific bylaw and SEC rule requirements.
Board of directors and corporate governance
Seven director nominees, all current directors, with diverse backgrounds in finance, law, manufacturing, and healthcare.
Five directors are independent under NYSE American standards; board held four meetings in 2024.
Standing committees: audit, compensation, executive, and nominating, each with defined roles and charters available online.
Nominating Committee considers shareholder-recommended candidates and values diversity, independence, and relevant experience.
Board leadership includes a non-executive chairman; independent directors meet separately and rotate chairing sessions.
Latest events from Chicago Rivet & Machine
- Returned to profitability in Q3 2025, but going concern risks persist amid industry challenges.CVR
Q3 20257 Nov 2025 - Q2 2024 returned to profit on improved margins, despite flat sales and ongoing risk from a product issue.CVR
Q2 202429 Sep 2025 - Sales fell 12.3% YoY in Q3 2024, with improved margins but a net loss of $1.45M.CVR
Q3 202429 Sep 2025 - Significant 2024 losses, liquidity risks, and operational restructuring amid industry headwinds.CVR
Q4 202429 Sep 2025 - Gross margin and net income improved despite lower sales, but liquidity risks persist.CVR
Q1 202529 Sep 2025 - Sales and margins declined in Q2 2025, raising going concern doubts despite cost actions.CVR
Q2 202529 Sep 2025